Brokerages Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Price Target at $19.50

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

CTNM has been the topic of several research reports. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Monday, April 20th. Robert W. Baird boosted their price target on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Finally, Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday.

Contineum Therapeutics Stock Down 3.4%

CTNM stock opened at $13.72 on Monday. The company has a 50-day simple moving average of $13.27 and a 200 day simple moving average of $12.70. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.33. The company has a market capitalization of $512.99 million, a P/E ratio of -7.04 and a beta of 0.89.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.16. Equities analysts anticipate that Contineum Therapeutics will post -1.88 EPS for the current year.

Institutional Investors Weigh In On Contineum Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CTNM. Strs Ohio bought a new stake in Contineum Therapeutics in the first quarter worth about $27,000. China Universal Asset Management Co. Ltd. acquired a new stake in Contineum Therapeutics during the 4th quarter worth about $43,000. Qube Research & Technologies Ltd acquired a new stake in Contineum Therapeutics during the 2nd quarter worth about $43,000. Marex Group plc acquired a new stake in Contineum Therapeutics during the 2nd quarter worth about $45,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Contineum Therapeutics during the 2nd quarter worth about $76,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.